Search on molecular target cancer drug from microbial secondary metabolites
| Project/Area Number |
20590107
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Iwaki Meisei University |
|---|
Principal Investigator |
KIM Yongpil Iwaki Meisei University, 薬学部・薬学科, 准教授 (70337997)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HAYASHI Masahiko いわき明星大学, 薬学部・薬学科, 教授 (20164965)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2010: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 分子標的治療薬 / 微生物二次代謝産物 / HIF-1α / 低酸素 / 乳がん / 血管内皮増殖因子 |
|---|
| Research Abstract |
It aimed at the treatment with high selective effect for cancer, HIF-1α (hypoxic inducible factor-1α) was made a molecular target from microbial secondary metabolites, we obtained a new type lead compounds. We expect that these compounds become a new type anti-cancer drug if anti-cancer mechanism action is clarified in the future.
|
Report
(4 results)
Research Products
(15 results)
-
-
-
-
-
[Journal Article] Cyslabdan, a New Potentiator of Imipenem Activity against Methicillin-resistant Staphylococcus aureus, Produced by Streptomyces sp. K04-0144 I. Taxonomy, Fermentation, Isolation and Structural Elucidation2009
Author(s)
A. Fukumoto, Y.P. Kim,, A. Matsumoto, Y. Takahashi, K. Shiomi, H. Tomoda S. Omura
-
Journal Title
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
